Early studies suggest Evusheld, the main monoclonal antibody treatment used to protect people with weakened immune systems from Covid, is likely to be ineffective against the new variants.
Public commenters will kick off Tuesday’s meeting, followed by Covis making its arguments for staying on the market and the FDA and advisory committee members questioning the company.
A panel of independent expert advisers will meet starting today to decide whether to recommend that Makena remain available for at least some patients.
India s made-in-the-USA nasal Covid vaccine politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
Worried about mental health? You re not alone politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.